Breaking News Instant updates and real-time market news.

GME

GameStop

$5.60

0.01 (0.18%)

, VFF

Village Farms

$7.03

0.07 (1.01%)

08:45
10/16/19
10/16
08:45
10/16/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: GameStop (GME) 47.59% +26.20, Village Farms International (VFF) 25.88% +6.21, PagerDuty (PD) 33.95% +4.70, TherapeuticsMD (TXMD) 25.90% +1.88, Alder BioPharmaceuticals (ALDR) 1.15% +0.83, Ballard Power (BLDP) 42.18% +0.68, Fastly Inc (FSLY) 37.28% +0.43, GW Pharmaceuticals (GWPH) 0.49% +0.24, Dropbox (DBX) 0.52% +0.24, and Zoom Video Communications (ZM) 96.10% +0.22.

GME

GameStop

$5.60

0.01 (0.18%)

VFF

Village Farms

$7.03

0.07 (1.01%)

PD

PagerDuty

$27.52

1.07 (4.05%)

TXMD

TherapeuticsMD

$3.92

(0.00%)

ALDR

Alder Biopharmaceuticals

$18.89

-0.03 (-0.16%)

BLDP

Ballard Power

$5.03

-0.02 (-0.40%)

FSLY

Fastly

$23.27

0.28 (1.22%)

GWPH

GW Pharmaceuticals

$120.07

3.82 (3.29%)

DBX

Dropbox

$19.41

0.09 (0.47%)

ZM

Zoom Video

$71.25

0.42 (0.59%)

  • 18

    Oct

  • 21

    Oct

  • 05

    Nov

  • 07

    Nov

  • 19

    Nov

  • 16

    Dec

  • 21

    Feb

GME GameStop
$5.60

0.01 (0.18%)

09/11/19
BARD
09/11/19
NO CHANGE
Target $6
BARD
Neutral
GameStop strategy updated but headwinds remain, says Baird
Baird analyst Peter Benedict noted GameStop reported another disappointing quarter but said management outlines a new strategy to improve profitability and drive deeper customer engagement. The analyst believes despite the new focus, the near-term impact of an eroding console cycle is likely to more than offset any material improvements. Benedict maintained his Neutral rating and $6 price target on GameStop shares.
09/03/19
LOOP
09/03/19
NO CHANGE
Target $4
LOOP
Hold
GameStop price target lowered to $4 from $7 at Loop Capital
Loop Capital analyst Anthony Chukumba lowered his price target on GameStop to $4 and kept his Hold rating ahead of its Q2 earnings next week, saying he is "increasingly concerned" about the company's "secular challenges". The analyst notes that his below-consensus EPS forecast of (35c) is based on expectations of a 10% SSS decline from lower sales in new videogame hardware and pre-owned products. Chukumba also expects investors to focus on the management's updates about its capital allocation plans and turnaround progress.
09/11/19
BNCH
09/11/19
NO CHANGE
Target $3
BNCH
Sell
GameStop price target cut to $3 after 'Chernobyl experience' Q2 at Benchmark
Benchmark analyst Mike Hickey, who called GameStop's disappointing Q2 sales report and weak FY19 profitability guidance a "Chernobyl experience," does not expect investor sentiment to improve and sees "questionable valuations on current fundamentals" as "inherently flawed." He maintains a Sell rating on the stock following the company's earnings report and lowered his price target on GameStop shares to $3 from $5.
09/12/19
LOOP
09/12/19
NO CHANGE
Target $4
LOOP
Hold
Loop Capital sees 'steep uphill' for recovery at GameStop
Loop Capital analyst Anthony Chukumba kept his Hold rating and $4 price target on GameStop, saying its below-consensus Q2 earnings and a cut in FY19 guidance offers "no compelling reason" to become more constructive on the stock. The analyst believes that the new management still has a "steep uphill" to turn around the company's performance and expects the company to struggle until the next video game cycle begins in late 2020, with no assurances that it will cure its "current ills".
VFF Village Farms
$7.03

0.07 (1.01%)

10/09/19
CHLM
10/09/19
NO CHANGE
CHLM
Vaping crisis underscores need to lift cannabis prohibition, says Craig-Hallum
Craig-Hallum analyst Eric Des Lauriers notes that the vaping crisis has taken a turn for the worse as severe respiratory illnesses have injured over 1,000 and claimed the lives of 18. Most patients reported using illicit vapes containing THC, the primary psychoactive compound in cannabis, while others reported using nicotine-only vapes, perplexing health officials, he notes. The analyst believes vape additives - not cannabis or nicotine - are causing the outbreak and researching the many additives found in vapes will take time, creating near-term headwinds. Ultimately, he sees certain additives being banned, not vaporizers as a whole. Longer-term, the vape crisis will be an industry tailwind, underscoring the need to regulate cannabis, he argues. The analyst sees less than 1% of Green Thumb Industries' (GTBIF) sales currently at risk, but in a worst-case scenario, the company could see about 25% of sales at risk. Even without vapes, he believes Green Thumb Industries can generate $1B-plus revenues with its existing licenses. Additionally, the analyst sees virtually no impact to Village Farms' (VFF) current revenue outlook.
07/22/19
CHLM
07/22/19
INITIATION
Target $30
CHLM
Buy
Village Farms initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Eric Des Lauriers initiated Village Farms with a Buy rating and a price target of $30, saying the company is becoming a "dominant" cannabis cultivator and has a large opportunity in U.S. hemp space. The analyst notes that Village Farms is exceeding cannabis yield and quality expectations and believes the company has a low-cost path to becoming a dominant cultivator, with potential to "far exceed" consensus estimates beginning in 2020.
06/13/19
ROTH
06/13/19
INITIATION
Target $25
ROTH
Buy
Village Farms initiated with a Buy at Roth Capital
Roth Capital analyst Scott Fortune started coverage of Village Farms with a Buy rating and $25 price target. The analyst notes that the company is converting its 10.6M sq. ft. tomato greenhouse infrastructure in North America, to new profitable cannabis/hemp cultivation. Established distribution and relationships with the biggest U.S. retailers allow potential new CBD product sales, he contends, adding that Village Farms can easily convert into cannabis cultivation once federally legal in the U.S. and Mexico.
PD PagerDuty
$27.52

1.07 (4.05%)

10/02/19
RHCO
10/02/19
INITIATION
RHCO
Hold
PagerDuty initiated with a Hold at SunTrust
SunTrust analyst Joel Fishbein initiated PagerDuty with a Hold rating and $32 price target.
10/02/19
RHCO
10/02/19
INITIATION
RHCO
SunTrust initiates infrastructure and security sector
SunTrust analyst Joel Fishbein initiated fourteen stocks in the infrastructure and security sector. Regarding infrastructure, he said he believes "we are in the 3rd inning of a multi year (even multi-decade) opportunity" and projected on-demand penetration of 70% by 2028, adding that "spending on cloud software is projected to grow at ~3x the overall software market rate, resulting in a greater than $208B market opportunity through 2025." However, Fishbein cautioned to "stay selective" as while he is bullish on the underlying trends, "too many investors are chasing too few stories." For cybersecurity, Fishbein noted that it remains a top priority for the corporations, and cited the IDC stating that "worldwide spending on security-related hardware, software, and services is forecast to reach $133.7B in 2022 at a compound annual growth rate of 9.9%." He believes that emerging vendors with innovative technology are growing much faster, and sees a "shift in spending from legacy security providers to next generation technology providers and multi-product platforms." The analyst started eight names with Buy ratings -- Atlassian (TEAM), New Relic (NEWR), ServiceNow (NOW), Splunk (SPLK), Palo Alto Networks (PANW), Rapid7 (RPD), SailPoint (SAIL), and Zscaler (ZS). The other six names Fishbein started with Hold ratings -- PagerDuty (PD), Check Point (CHKP), FireEye (FEYE), Proofpoint (PFPT), Qualys (QLYS), and Tenable Holdings (TENB).
10/15/19
BARD
10/15/19
INITIATION
Target $31
BARD
Outperform
PagerDuty started with Outperform, positioned for sustainable growth says Baird
Baird analyst Rob Oliver initiated coverage of PagerDuty with an Outperform rating and $31 price target. The analyst said the company is turning nearly every company into a software company. Oliver said its vision, user reputation and low-cost low-friction sales model positions them well for strong sustainable growth.
10/14/19
BARD
10/14/19
INITIATION
Target $31
BARD
Outperform
PagerDuty initiated with an Outperform at Baird
Baird analyst Rob Oliver initiated coverage of PagerDuty with an Outperform rating and $31 price target.
TXMD TherapeuticsMD
$3.92

(0.00%)

07/15/19
JEFF
07/15/19
NO CHANGE
Target $3
JEFF
Hold
TherapeuticsMD price target lowered to $3 from $4 at Jefferies
Jefferies analyst Chris Howerton lowered his price target for TherapeuticsMD to $3 from $4 following the company's recent 2019 guidance and clarity on Annovera. The analyst's base-case for Annovera assumes new contraceptive category status and peak estimates of 35%, $315M, and 60% for penetration, revenue and net margin, respectively. He says the guidance gives him pause and keeps a Hold rating on the shares.
08/07/19
CANT
08/07/19
NO CHANGE
Target $13
CANT
Overweight
Cantor reiterates $13 price target on TherapeuticsMD after 'solid' quarter
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on TherapeuticsMD with a $13 price target following the company's "solid quarter of execution." TherapeuticsMD in premarket trading is up 10%, or 18c, to $2.05. Upward earnings revisions and multiple expansion to levels not reflected in consensus forecasts will drive the stock higher, Chen tells investors in a research note. The analyst anticipates better than expected uptake for Imvexxy, Bijuva and Annovera in 2019 and beyond.
09/27/19
STFL
09/27/19
NO CHANGE
Target $20
STFL
Buy
Stifel stays bullish on TherapeuticsMD after management meetings
After hosting meetings with TherapeuticsMD (TXMD), Stifel analyst Annabel Samimy said she maintains her bullish stance and reiterated a Buy rating on the stock with a $20 price target. Imvexxy "finally" got commercial coverage at CVS (CVS), Bijuva was added at Cigna (CI), and Annovera distribution begins with 40% unrestricted coverage, noted Samimy, who sees the company being on track to meet its 2019 guidance and "see rapid growth from this point forward. Additionally, a survey produced "multiple favorable signals for future uptake," leaving her increasingly confident that TherapeuticsMD can reach a leadership position in Women's Health, said Samimy.
06/25/19
STFL
06/25/19
NO CHANGE
STFL
Evolus can benefit from 'distraction' at Allergan, says Stifel
After AbbVie (ABBV) announced its intention to acquire Allergan (AGN), Stifel analyst Annabel Samimy said the former clearly sees the latter's Medical Aesthetics business "as a premier, durable, cash-pay franchise and a leader in its field." However, she noted that AbbVie committed to keeping it as a separate business under the Allergan name, which leads Samimy to believe that a spinoff of aesthetics remains a possibility. She also said she would expect "meaningful distraction" at Allergan, "as typical in the midst of an acquisition," which can benefit competitor Evolus (EOLS) as it launches Jeuveau. Samimy, who concluded that she sees today's news potentially bringing interest back to the "washed out" biopharma group, names Revance (RVNC), Aerie Pharmaceuticals (AERI), TherapeuticsMD (TXMD) and Kala Pharmaceuticals (KALA) as being among the potentially attractive targets.
ALDR Alder Biopharmaceuticals
$18.89

-0.03 (-0.16%)

09/17/19
UBSW
09/17/19
UPGRADE
Target $19.5
UBSW
Neutral
Alder Biopharmaceuticals upgraded to Neutral from Sell at UBS
UBS analyst Andrew Ang upgraded Alder Biopharmaceuticals (ALDR) to Neutral from Sell and raised his price target for the shares to $19.50 from $9 following the company's agreement to be acquired by Lundbeck (HLUYY).
09/17/19
FBCO
09/17/19
NO CHANGE
Target $19
FBCO
Neutral
Alder Biopharmaceuticals price target raised to $19 from $11 at Credit Suisse
Credit Suisse analyst Evan Seigerman raised his price target for Alder Biopharmaceuticals to $19 from $11 to reflect the agreement reached for Lundbeck to acquire Alder. The analyst continues to believe that eptinezumab is likely to be approved by the EMA by 2021, entitling shareholders to receive $2/share in connection with the CVR. He reiterates a Neutral rating on the shares.
09/17/19
WBLR
09/17/19
NO CHANGE
WBLR
Outperform
William Blair reiterates Outperform on Biohaven after Alder buyout
William Blair analyst Tim Lugo views Lundbeck's (HLUYY) acquisition of Alder Biopharmaceuticals (ALDR) as indicative of continued interest in the calcitonin gene-related peptide space from strategic buyers given the IV dosing and what is an increasingly competitive space for biologics. Following the deal, the analyst reiterates an Outperform rating on Biohaven Pharmaceutical (BHVN). The analyst sees an "active" Q4 for the company, which is expected to include the readout of the Phase III trial of rimegepant for the prevention of episodic migraine, top-line results from a Phase II/III trial of intranasal CGRP therapy BHV-3500, and completion of enrollment in Phase II/III trials of troriluzole for the treatment of obsessive-compulsive disorder, generalized anxiety disorder, and Alzheimer's disease.
09/17/19
09/17/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alder Biopharmaceuticals (ALDR) upgraded to Neutral from Sell at UBS and to Equal Weight from Underweight at Morgan Stanley. 2. Snap (SNAP) upgraded to Neutral from Negative at Susquehanna with analyst Shyam Patil saying his recent advertising channel checks have suggested that Snap's "solid" growth has continued in Q3 with expectations for continued progress in Q4. 3. Splunk (SPLK) upgraded to Overweight from Neutral at JPMorgan with analyst Mark Murphy saying he expects a bookings growth rebound in the second half of 2019 and has a favorable view of the company's transition to a recurring/renewable model. 4. Circor (CIR) upgraded to Overweight from Sector Weight at KeyBanc analyst Jeffrey Hammond saying he sees a wide range of potential outcomes that generally support a higher stock price, including arriving at 2020 targets, or equivalent figures net of divestitures, divesting the Energy business to accelerate deleveraging and refocus the portfolio around less volatile Industrial and Aero assets, or falling short of targets and/or failing to monetize the Energy assets, commencing a change of leadership and/or renewed takeout chatter. 5. Burlington Stores (BURL) and TJX (TJX) upgraded to Neutral from Sell at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BLDP Ballard Power
$5.03

-0.02 (-0.40%)

07/01/19
ROTH
07/01/19
DOWNGRADE
ROTH
Sell
Ballard Power downgraded to Sell from Neutral at Roth Capital
Roth Capital analyst Craig Irwin downgraded Ballard Power to Sell from Neutral and maintained a $3 price target citing recent share strength and a valuation near 15-year highs.
07/01/19
07/01/19
DOWNGRADE
Target $3

Sell
Ballard Power downgraded to Sell on valuation at Roth Capital
As previously reported, Roth Capital analyst Craig Irwin downgraded Ballard Power to Sell from Neutral, while maintained a $3 price target on the shares, as he believes positive China fuel cell market exposure does not justify the valuation. Current valuation is near 15-year highs, and is unlikely to see internet-type multiples last seen in 2001, he contends. While the analyst agrees the company's supply relationships with groups like Weichai and BroadOcean position it well to benefit from China market tailwinds, Ballad does not offer a hydrogen electrolyzer solutions necessary for refueling infrastructure.
11/02/18
RILY
11/02/18
DOWNGRADE
Target $3
RILY
Neutral
Ballard Power downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Carter Driscoll downgraded Ballard Power Systems to Neutral and lowered his price target for the shares to $3 from $5. Following the company's Q3 results, the analyst believes the timing of its China ramp is more uncertain.
FSLY Fastly
$23.27

0.28 (1.22%)

08/14/19
PIPR
08/14/19
INITIATION
Target $21
PIPR
Overweight
Fastly initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst James Fish started Fastly with an Overweight rating and $21 price target. The company provides a CDN/edge compute platform that delivers faster and safer applications and websites to end-users, Fish tells investors in a research note. He believes Fastly will benefit from "strong, sustainable" underlying market dynamics as well as the "evolutionary shift" towards edge workloads. The analyst views the recent pullback in the shares as an attractive opportunity.
08/14/19
08/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tenet (THC) reinstated with a Neutral at Goldman Sachs. 2. WWE (WWE) initiated with a Buy at Rosenblatt. 3. iHeartMedia (IHRT) initiated with a Buy at BofA/Merrill. 4. Fastly (FSLY) initiated with an Overweight at Piper Jaffray. 5. Amarin (AMRN) initiated with an Outperform at SVB Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/19
PIPR
10/11/19
DOWNGRADE
Target $24
PIPR
Neutral
Fastly downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst James Fish downgraded Fastly to Neutral from Overweight with a price target of $24, up from $21. The stock's "large out-performance" over the last few months has driven valuation towards a "fair-value," Fish tells investors in a research note. The analyst is making a valuation call as he continues to like the prospects of the business longer-term.
10/11/19
PIPR
10/11/19
DOWNGRADE
Target $24
PIPR
Neutral
Fastly downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst James Fish downgraded Fastly to Neutral from Overweight with a price target of $24, up from $21. The stock's "large out-performance" over the last few months has driven valuation towards a "fair-value," Fish tells investors in a research note. The analyst is making a valuation call as he continues to like the prospects of the business longer-term.
GWPH GW Pharmaceuticals
$120.07

3.82 (3.29%)

10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
10/14/19
LEER
10/14/19
NO CHANGE
LEER
Outperform
Investor concerns related to GW Pharmaceuticals 'misplaced,' says SVB Leerink
SVB Leerink analyst Marc Goodman notes that it has been a "tough late summer/fall" for GW Pharmaceuticals, as misplaced investor concerns have beaten up the stock significantly and Friday was no different. The analyst points out that the concern on Friday started as investors checked on the weekly Symphony Rx data for the first week of October, which indicated a significant decline from the previous week. He was able to confirm with the company that a "very significant specialty pharmacy" had stopped reporting weekly Rxs to the data providers that flow into Symphony Rx, which makes sense given the surprisingly abrupt Rx trend on Friday. Goodman still believes Epidiolex can be a "significant" product in epilepsy. He reiterates an Outperform rating on the shares.
09/27/19
OPCO
09/27/19
NO CHANGE
Target $233
OPCO
Outperform
GW Pharmaceuticals price target lowered to $233 from $239 at Oppenheimer
Oppenheimer analyst Esther Rajavelu reiterated an Outperform rating on GW Pharmaceuticals and lowered her price target to $233 from $239 given that the company is several months into its U.S. Epidiolex launch. In a research note to investors, Rajavelu says she believes Epidiolex U.S. uptake continues to progress well, and awaits management comments on its EU pricing and commercial strategy.
09/19/19
HCWC
09/19/19
NO CHANGE
Target $23
HCWC
Buy
Zynerba selloff on open-label data for Zygel 'unwarranted,' says H.C. Wainwright
After Zynerba (ZYNE) announced yesterday top line results from the open label Phase 2 clinical trial that assessed the safety and efficacy of Zygel in developmental and epileptic encephalopathies, or DEE, H.C. Wainwright analyst Oren Livnat said the shares have been "punished," which he sees as "unwarranted" since he views the data as encouraging. Investors, comparing Zygel head-to-head with GW Pharma's (GWPH) Epidiolex, appear to be concluding that Zygel looks less efficacious, which he doesn't think is necessarily the case. Furthermore, this line of "reasoning entirely misses the point of this study," which were identifying an efficacy signal and confirming Zygel's likely superior safety profile vs Epidiolex, both of which he thinks Zynerba achieved. Livnat reiterated a Buy rating on Zynerba shares.
DBX Dropbox
$19.41

0.09 (0.47%)

09/27/19
ADAM
09/27/19
NO CHANGE
Target $35
ADAM
Buy
Dropbox negative investor sentiment will be proven incorrect, says Canaccord
Canaccord analyst Richard Davis attended the Dropbox analyst day and came away with his conclusion unchanged; that the overwhelmingly negative investor sentiment is overwrought and will be proven incorrect. The analyst cited new product enhancements and a current valuation that implies an attractive risk/reward. Davis reiterated his Buy rating and $35 price target on Dropbox shares.
10/03/19
ADAM
10/03/19
NO CHANGE
Target $35
ADAM
Buy
Dropbox still our favorite value stock, says Canaccord
Canaccord analyst Richard Davis noted Dropbox announced that it hired two new development Senior Vice-Presidents and he believes the hires are immaterial but given the market action, he is waiting to see investor's reaction. He said the current valuation is below its growth rate and the company has just raised its price suggesting no change to fundamentals. Davis reiterated his Buy rating and $35 price target on Dropbox shares.
10/08/19
JEFF
10/08/19
INITIATION
Target $32
JEFF
Buy
Dropbox assumed with a Buy rating at Jefferies
Jefferies analyst Brent Thill assumed coverage of Dropbox with a Buy rating and unchanged price target of $32. The analyst last night assumed coverage of the Software industry and adjusted some of his ratings to be more defensive in light of valuation and macroeconomic concerns. However, he remains positive on the industry and believes that the fundamentals of businesses in the space are "very strong."
09/26/19
09/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dropbox (DBX) assumed with an Outperform at RBC Capital. 2. Rigel Pharmaceuticals (RIGL) assumed with an Overweight at JPMorgan. 3. Aaron's (AAN) initiated with a Buy at BofA/Merrill. 4. Cooper-Standard (CPS) resumed with a Buy at Roth Capital. 5. Carvana (CVNA) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ZM Zoom Video
$71.25

0.42 (0.59%)

10/08/19
RBCM
10/08/19
NO CHANGE
Target $95
RBCM
Sector Perform
Zoom Video price target lowered to $95 from $99 at RBC Capital
RBC Capital analyst Alex Zukin lowered his price target on Zoom Video to $95 and kept his Sector Perform rating after meeting with its CFO and VP of Investor Relations. The analyst notes that the company has posted two consecutive quarters of strong results and also has several levers to generate growth and profitability at scale that include an opportunity with Zoom Phone and international expansion. However, the analyst is concerned with Zoom Video's competition from larger legacy firms and notes its "limited operating history", saying that its new price target reflects a more "consistent" enterprise value to expected sales multiple premium relative to the "high growth group."
09/16/19
09/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Finance Trust (AFIN) initiated with a Neutral at B. Riley FBR. 2. Investors Real Estate (IRET) initiated with a Buy at BTIG. 3. Preferred Apartment (APTS) initiated with a Buy at National Securities. 4. Enphase Energy (ENPH) initiated with an Overweight at JPMorgan. 5. Zoom Video (ZM) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/19
GSCO
10/11/19
DOWNGRADE
Target $66
GSCO
Sell
Crowdstrike downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Heather Bellini downgraded Crowdstrike Holdings (CCRWD) to Sell from Neutral with a price target of $66, down from $83. The shares closed Thursday down $1.67 to $61.41. While CrowdStrike is very well positioned in the market for endpoint security, and can continue to post upside to estimates, a "blue sky analysis" suggests this is likely priced in at current share levels, Bellini tells investors in a research note. The analyst this morning also upgraded Workday (WDAY) to Buy from Neutral. Her "Blue Sky analyses" show that the companies with the highest potential upside to 2020 estimates are Zoom Video (ZM), Slack Technologies (WORK), and Elastic (ESTC).
09/30/19
BOFA
09/30/19
DOWNGRADE
Target $21
BOFA
Underperform
BofA/Merrill downgrades 8x8 to Underperform, cuts price target to $21
As previously reported, BofA Merrill Lynch analyst Nikolay Beliov downgraded 8x8, Inc. (EGHT) to Underperform from Neutral and lowered his price target PO to $21 from $28, noting that Q1 subscription growth was only in-line "despite a beat-and-raise set-up" and that both mid-market ARR growth and enterprise ARR growth slowed in Q1 compared to the prior year. Additionally, he sees the company have "one of the worst sales efficiencies amongst peers," which makes it harder trying to compete with Zoom Video (ZM) and Twilio (TWLO), Beliov tells investors.

TODAY'S FREE FLY STORIES

09:18
11/20/19
11/20
09:18
11/20/19
09:18
Conference/Events
House Ways & Means Committee holds a hearing »

The Trade Subcommittee…

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
11/20/19
11/20
09:18
11/20/19
09:18
Options
Overnight activity included 616 trades in SPX and 14 trades in VIX »

616 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$28.73

-1.43 (-4.74%)

09:17
11/20/19
11/20
09:17
11/20/19
09:17
Recommendations
Urban Outfitters analyst commentary  »

Urban Outfitters price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TEVA

Teva

$10.29

-0.055 (-0.53%)

09:17
11/20/19
11/20
09:17
11/20/19
09:17
Recommendations
Teva analyst commentary  »

Teva 'offered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:16
11/20/19
11/20
09:16
11/20/19
09:16
Conference/Events
House Financial Services Committee to hold a hearing »

The Subcommittee on…

WBS

Webster Financial

$47.96

0.08 (0.17%)

09:14
11/20/19
11/20
09:14
11/20/19
09:14
Conference/Events
Webster Financial management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

URBN

Urban Outfitters

$28.73

-1.43 (-4.74%)

09:14
11/20/19
11/20
09:14
11/20/19
09:14
Recommendations
Urban Outfitters analyst commentary  »

Urban Outfitters price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

LOW

Lowe's

$113.41

-1.62 (-1.41%)

09:13
11/20/19
11/20
09:13
11/20/19
09:13
Hot Stocks
Lowe's says saw 'consistent growth across the business' in Q3 »

Says: Focus on Pro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

UPS

UPS

$120.54

-2.265 (-1.84%)

09:13
11/20/19
11/20
09:13
11/20/19
09:13
Conference/Events
UPS management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

09:12
11/20/19
11/20
09:12
11/20/19
09:12
Conference/Events
World of Business Ideas to hold a forum »

World Business Forum will…

AVB

AvalonBay

$217.04

1.81 (0.84%)

09:11
11/20/19
11/20
09:11
11/20/19
09:11
Recommendations
AvalonBay analyst commentary  »

AvalonBay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKS

Skyworks

$96.66

-0.76 (-0.78%)

09:11
11/20/19
11/20
09:11
11/20/19
09:11
Conference/Events
Skyworks management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

SPXC

SPX Corporation

$47.02

-0.35 (-0.74%)

09:08
11/20/19
11/20
09:08
11/20/19
09:08
Conference/Events
SPX Corporation management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

ZIXI

Zix

$7.31

0.18 (2.52%)

, MCX

MC Shipping

$24.75

(0.00%)

09:06
11/20/19
11/20
09:06
11/20/19
09:06
Conference/Events
Three Part Advisors to hold a conference »

Southwest Ideas…

ZIXI

Zix

$7.31

0.18 (2.52%)

MCX

MC Shipping

$24.75

(0.00%)

VOLT

Volt Information Sciences

$2.73

-0.02 (-0.73%)

CVA

Covanta

$14.65

-0.065 (-0.44%)

PCTI

PCTEL

$8.87

-0.12 (-1.33%)

IVAC

Intevac

$6.00

0.15 (2.56%)

RUBI

Rubicon Project

$7.77

-0.065 (-0.83%)

CHRA

Charah Solutions

$2.32

-0.18 (-7.20%)

TLRA

Telaria

$7.66

-0.18 (-2.30%)

GHM

Graham

$22.60

0.215 (0.96%)

HY

Hyster-Yale Materials

$59.11

1.24 (2.14%)

SDPI

Superior Drilling

$0.88

-0.0355 (-3.87%)

TPB

Turning Point Brands

$25.57

-1.98 (-7.19%)

KLIC

Kulicke & Soffa

$23.19

0.44 (1.93%)

SMTX

SMTC Corp.

$2.85

0.12 (4.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 26

    Feb

SPXC

SPX Corporation

$47.02

-0.35 (-0.74%)

09:06
11/20/19
11/20
09:06
11/20/19
09:06
Conference/Events
SPX Corporation management to meet with Buckingham »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

STNG

Scorpio Tankers

$32.43

1.28 (4.11%)

09:06
11/20/19
11/20
09:06
11/20/19
09:06
Hot Stocks
Scorpio Tankers announces purchase of call options by company president »

Last night, Scorpio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIDD

Middleby

$114.55

-0.21 (-0.18%)

09:04
11/20/19
11/20
09:04
11/20/19
09:04
Hot Stocks
Middleby acquires Brava Home »

Middleby announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

09:04
11/20/19
11/20
09:04
11/20/19
09:04
Hot Stocks
Tandem Diabetes announces Health Canada approval of t:slim X2 pump »

Tandem Diabetes announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEEL

Seelos Therapeutics

$0.87

0.012 (1.39%)

09:03
11/20/19
11/20
09:03
11/20/19
09:03
Hot Stocks
Seelos Therapeutics announces initial dosing of Phase 1 DDI study »

Seelos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

URBN

Urban Outfitters

$28.73

-1.43 (-4.74%)

09:03
11/20/19
11/20
09:03
11/20/19
09:03
Recommendations
Urban Outfitters analyst commentary  »

Urban Outfitters'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BFC

Bank First National

$68.94

0.67 (0.98%)

09:03
11/20/19
11/20
09:03
11/20/19
09:03
Hot Stocks
Bank First National to acquire Timberwood Bank »

Bank First signed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$51.69

0.12 (0.23%)

, INSM

Insmed

$20.64

0.54 (2.69%)

09:03
11/20/19
11/20
09:03
11/20/19
09:03
Conference/Events
SVB Leerink to hold a bus tour »

13th Annual POLARxPRESS…

BHVN

Biohaven Pharmaceutical

$51.69

0.12 (0.23%)

INSM

Insmed

$20.64

0.54 (2.69%)

MGNX

MacroGenics

$8.65

0.2 (2.37%)

MRK

Merck

$84.64

0.52 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

SBPH

Spring Bank Pharmaceuticals

$3.23

0.235 (7.86%)

09:02
11/20/19
11/20
09:02
11/20/19
09:02
Hot Stocks
Spring Bank announces dosing of patients in Phase 1 trial of SB 11285 »

Spring Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUX

McEwen Mining

$1.51

-0.015 (-0.98%)

09:01
11/20/19
11/20
09:01
11/20/19
09:01
Syndicate
McEwen Mining 37.75M share Spot Secondary priced at $1.325 »

Roth Capital and Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SLRC

Solar Capital

$20.53

0.04 (0.20%)

09:01
11/20/19
11/20
09:01
11/20/19
09:01
Conference/Events
Solar Capital management to meet with Compass Point »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.